Swedish Orphan Biovitrum AB (publ) (SOBI.ST) stock analysis

In our weekly check, Swedish Orphan Biovitrum AB (publ) is graded B (A to F). Of 24 checks on debt, profit, cash flow and trend: 16 pass, warnings: 4, red flags: 4.

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ) is a Healthcare company (Drug Manufacturers - Specialty & Generic) based in Sweden, listed on STO as SOBI.ST.

What our checks show for SOBI.ST

Red flags

• The net margin fell by 12.7 points over 5 years, to 4.5%: the company keeps less of each sale as profit.
• The gross margin fell by 31.7 points, to 45.9%: costs are rising faster than prices.
• The net margin is only 4.5%: little room if costs rise.
• The stock has fallen as much as 78% from a peak. Would you have held through that?

Warning signs

• Earnings per share fell 22.5% a year over the last 3 years.
• Net profit fell 19.4% a year over the last 3 years.
• Recovering from its deepest fall took about 1.8 years.
• Thinly traded (about 302 thousand shares a day): buying and selling can move the price.

Strengths

• Net debt is only 1.2x a year of EBITDA: the balance sheet has room.
• Operating profit covers interest 18.3 times over.
• Operating cash flow is 6.2x net profit: the profit arrives as real cash.
• Analysts expect earnings per share to grow about 114% a year over the next years.
• Analysts expect the net margin to improve by 19.7 points from today's 4.5%.
• Revenue grew 17.7% a year over the last 3 years.

Next earnings report: 2026-10-27

Similar companies

6618.HK · 1177.HK · RADL3.SA · RPRX

Questions

What grade does Swedish Orphan Biovitrum AB (publ) (SOBI.ST) have?

In our weekly check, Swedish Orphan Biovitrum AB (publ) is graded B (A to F). Of 24 checks on debt, profit, cash flow and trend: 16 pass, warnings: 4, red flags: 4. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of SOBI.ST stock?

This week's biggest flags for Swedish Orphan Biovitrum AB (publ): Margins falling, Gross margin falling, Thin margins. In total 8 of 24 checks show a warning or a red flag.

What does Swedish Orphan Biovitrum AB (publ) do?

Swedish Orphan Biovitrum AB (publ) is a Healthcare company (Drug Manufacturers - Specialty & Generic) based in Sweden, listed on STO as SOBI.ST.

When does Swedish Orphan Biovitrum AB (publ) report earnings next?

The next earnings report is expected on 2026-10-27. We re-run the checks every week, so the grade can change after it.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-24

Open the full analysis